Latest in Finance

Sanofi completes acquisition of Blueprint Medicines

Sanofi announces the completion of its acquisition of Blueprint Medicines Corporation, adding to its portfolio a commercialised medicine and the expertise of a company specialising in systemic mastocytosis (SM) and other KIT-driven diseases

Find out more

SPT Labtech and Cavendish combine technologies to improve the cell-based assay design process

By combining technologies, the companies hope to optimise the cell assay development workflow with automation
See more

Evestia Clinical to merge with Atlantic Research Group

The merger delivers on Evestia Clinical’s strategy of targeted growth through the expansion of services, enhanced technology and broadened geographical reach

Amphista Therapeutics reaches research milestone and triggers a milestone payment from Merck

Collaboration focuses on the discovery of novel, non-CRBN/VHL, Targeted Glue degraders for oncology and immunology indications

Strategic investment by Bain Capital, Kohlberg and Mubadala fuels PCI Pharma Services’ expansion

This financial injection is expected to cement PCI’s position in the CDMO arena

Pila Pharma bags nearly £1.5m to aid obesity drug development

The ex-Novo Nordisk researcher-founded biotech will use the money to expand its obesity clinical pipeline

Ofichem Group to acquire drug formulation development specialist, Avivia

Ofichem will now be able to offer its clients a range of early-stage development services, from analytical method development to excipient characterisation

Ciloa bags €6.5m in funding to progress obesity therapy's clinical development

The company will now progress APN-sEV into clinical trials, while scaling up its GMP manufacture to a large scale

Siemens completes acquisition of Dotmatics

Acquisition is another milestone of Siemens’ ONE Tech Company program expanding Siemens’ offerings into the life sciences industry with stronger customer focus, faster innovations and higher profitable growth

A forward-thinking approach to reducing downtime and costs in the pharmaceutical industry

Implementing predictive maintenance and a lifecycle package can significantly reduce both downtime and costs in the pharmaceutical industry, emphasises Benoit Dehaene from GEA Pharma & Healthcare

Latest posts in Finance

Laverock Therapeutics expands seed funding and announces key milestone progress

Functional data has been generated, demonstrating enhanced tumour control for both primary T-cell and Macrophage programmes, representing key milestones

Stalicla secures financing to advance precision medicine neurodevelopmental disorder programmes

STALICLA SA has announced the successful closing of a CHF 2m financing led by Addex Therapeutics

BioCryst to sell Orladeyo to Neopharmaed Gentili for $264m

The hereditary angiodema-targeting prescription medication is being sold to pay off term debt from Pharmakon

PSG acquires sanitary pump manufacturer, ipp Pump Products

The company will now be able to offer its client base a range of sanitary pumps for gentle, contactless fluid handling

IMCD bolsters API portfolio with Trichem Healthcare acquisition

This acquisition will bolster IMCD's portfolio of specialty pharmaceutical ingredients

Superlab Suisse to open new facility at Campus Biotech in Geneva in January 2026

Superlab Suisse has announced the opening of its fourth Swiss laboratory facility at Campus Biotech in Geneva, which will be ready for move-in by January 2026
You need to be a subscriber to read this article.
Click here to find out more.

Tariff tensions: creating a turning point for domestic pharma manufacturing

The pharmaceutical industry is at a critical juncture. As potential US tariffs threaten its longstanding strategy of low-cost global sourcing, companies are being forced to rethink their approach to supply chain resilience

Bionova Scientific expands capacity and enters advanced therapies market

Third Cytiva FlexFactory manufacturing platform will help the CDMO to meet the rising demand for genomic medicines

Mabion launches €500k oncology services contest at Bio International

The competition is designed to help biotechs scale and commercialise their recombinant protein-based oncology therapeutics

Orion chooses Shilpa Biocare to supply recombinant human albumin protein

Orion will now be responsible for the commercialisation of Shilpa's non-human, virus-free albumin protein across Europe

Chiesi Group licenses two of Key2Brain's BBB-crossing therapeutic candidates

Chiesi will now globally develop and commercialise Key2Brain's therapeutic candidates for ultra-rare liposomal conditions, alpha-mannosidosis and Krabbe disease

Zydus new CDMO business to acquire two CMC biologics facilities from Agenus

Through the acquisition of Agenus' two Californian biologics manufacturing facilities, Zydus will place its first manufacturing footprint in the key US CDMO market

Sponsor content

Gerresheimer reports H1 2025 growth driven by Bormioli Pharma acquisition

Cosmetics and oral liquids markets dampen organic revenue but outlook remains strong

Almac completes a multi-million-pound investment enhancing cold chain capabilities in Craigavon

Almac Clinical Services, part of the Almac Group, has completed a multi-million-pound investment to enhance cold chain capabilities at its global headquarters in...

CARBOGEN AMCIS accelerates manufacturing capacity with CHF 25.5 million co-investment at Swiss sites

CARBOGEN AMCIS is pleased to announce a strategic co-investment of more than CHF 25 million with a long-standing Japanese customer to expand manufacturing capabilities at...

Gerresheimer adjusts guidance for Financial Year 2025

Gerresheimer is adjusting its guidance for 2025 due to continuing subdued demand in the cosmetics market and a decline in demand for plastic containment solutions for oral...

Almac Group hits record £1 billion revenue milestone

Strong financials support expansion in manufacturing and clinical capabilities

Lonza publishes updated 2024 financials ahead of One Lonza reporting

New CDMO platform structure supports upcoming half-year 2025 results

Vetter once again named best managed company

The award jury recognises strategic and sustainable corporate management

SCHOTT Pharma delivers strong second quarter of fiscal year 2025

SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, today published its results for the second quarter of the fiscal year 2025

Gerresheimer: Bormioli Pharma boosts revenues and earnings

Gerresheimer recorded a jump in revenues and earnings due to the first-time consolidation of Bormioli Pharma, which was acquired in 2024

Piramal Pharma Limited announces results for Q3 and 9M FY25

Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635) announced its standalone and consolidated results for the Third Quarter (Q3) and Nine Months (9M) ended 31st December...

Vetter strengthens senior management team for growth

Three new managing directors to support global sustainable development

Piramal Pharma Limited reports robust growth in CDMO and sustainability initiatives

US$80 million Lexington expansion to double sterile fill-finish capacity